62,734
edits
Changes
no edit summary
|-
| 2016 (December) || || || Study || A study finds the {{w|rVSV-ZEBOV vaccine}} against {{w|Ebola virus disease}} to be 95-100% effective, making it the first proven vaccine against the disease.<ref name="TL-20161222">{{cite journal |vauthors=Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, Carroll MW, Dean NE, Diatta I, Doumbia M, Draguez B, Duraffour S, Enwere G, Grais R, Gunther S, Gsell PS, Hossmann S, Watle SV, Kondé MK, Kéïta S, Kone S, Kuisma E, Levine MM, Mandal S, Mauget T, Norheim G, Riveros X, Soumah A, Trelle S, Vicari AS, Røttingen JA, Kieny MP|display-authors=6 |title=Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!) |journal = Lancet |volume = 389 |issue = 10068 |pages = 505–518 |year = 2017 |pmid = 28017403 |pmc = 5364328 |doi = 10.1016/S0140-6736(16)32621-6 }}</ref><ref name="CNN-2016122">{{cite news |last=Berlinger |first=Joshua |title=Ebola vaccine gives 100% protection, study finds |url=http://www.cnn.com/2016/12/22/health/ebola-vaccine-study/index.html |date=22 December 2016 |work=[[CNN]] |accessdate=25 April 2018}}</ref> ||
|-
| 2018 || December 21 || {{w|Diphtheria}}, {{w|tetanus}}, {{w|pertussis}}, {{w|polio}}, [[w:Haemophilus influenzae|haemophilus influenzae type b (Hib)}}, {{w|hepatitis B}} || Vaccine approval || "FDA approved Vaxelis (MCM Vaccine Co), a new combination DTaP-IPV-Hib-HepB vaccine for use in children 6 wks–4 yrs of age."<ref>{{cite web |title=Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type b Conjugate, and Hepatitis B Vaccine, and Guidance for Use in Infants |url=https://www.medscape.com/viewarticle/924906 |website=medscape.com |accessdate=1 June 2020}}</ref> || {{w|United States}}
|-
| 2019 || January 14 || {{w|Tetanus}}, {{w|diphtheria}}, {{w|pertussis}} || Vaccine approval || "FDA approved expanded use of Sanofi's Adacel Tdap vaccine for a second dose in people ages 10 through 64 years of age."<ref>{{cite web |title=FDA Approves Expanded Use of Adacel® (Tdap) Vaccine for Repeat Vaccination |url=http://www.news.sanofi.us/2019-01-14-FDA-Approves-Expanded-Use-of-Adacel-R-Tdap-Vaccine-for-Repeat-Vaccination |website=news.sanofi.us |accessdate=1 June 2020}}</ref> ||
